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OBJECTIVES We sought to determine whether mechanical unloading of the failing human heart with a left
ventricular assist device (LVAD) results in significant changes in overall left ventricular gene
expression.
BACKGROUND Mechanical circulatory support by LVAD in end-stage human heart failure (HF) can result
in beneficial reverse remodeling of myocardial structure and function. The molecular
mechanisms behind this salutary process are not well understood.
METHODS Left ventricular samples from six male patients were harvested during LVAD placement and
subsequently at the time of explantation. Cardiac gene expression was determined using
oligonucleotide microarrays.
RESULTS Paired t test analysis revealed numerous genes that were regulated in a statistically significant
fashion, including the downregulation of several previously studied genes. Further statistical
analysis revealed that the overall gene expression profiles could significantly distinguish pre-
and post-LVAD status. Interestingly, the data also identified two distinct groups among the
pre-LVAD failing hearts, in which there was blind segregation of patients based on HF
etiology. In addition to the substantial divergence in genomic profiles for these two HF
groups, there were significant differences in their corresponding LVAD-mediated regulation
of gene expression.
CONCLUSIONS Support with an LVAD in HF induces significant changes in myocardial gene expression, as
pre- and post-LVAD hearts demonstrate significantly distinct genomic footprints. Thus,
reverse remodeling is associated with a specific pattern of gene expression. Moreover, we
found that deoxyribonucleic acid microarray technology could distinguish, in a blind manner,
patients with different HF etiologies. Expansion of this study and further development of
these statistical methods may facilitate prognostic prediction of the individual patient
response to LVAD support. (J Am Coll Cardiol 2003;41:1096–106) © 2003 by the
American College of Cardiology Foundation
Although heart transplantation is an effective interventional
therapy for end-stage heart failure (HF), donor hearts are
consistently in limited supply. Hence, patients who experi-
ence clinical deterioration before transplant availability are
frequently given mechanical circulatory support in the form
of a left ventricular assist device (LVAD), employed as a
See page 1107
“bridge to transplant.” To date, the utility, efficacy, and
safety of LVAD support as a bridge to transplant has been
widely recognized (1,2). Importantly, LVAD support, sim-
ilar to all drugs that exert beneficial effects on mortality in
patients with HF, also favorably impacts the left ventricular
(LV) remodeling process (3–6). Recent evidence has dem-
onstrated that unloading the LV in patients with end-stage
HF by LVAD support can lead toward reverse remodeling
of myocardial structure and function (6–15). Studies of
LVAD-mediated reverse remodeling have described
changes such as decreased myocyte size (8,12,14), increased
myocyte contractility (8,13), improved mitochondrial func-
tion (15), decreased myocyte apoptosis, and normalized
mitogen-activated protein kinase signaling (12). However,
the overall molecular mechanisms of the reverse remodeling
process are not yet well understood. Owing to the beneficial
effects of LVAD support, it is likely that identification of
the mechanisms responsible for the associated reverse re-
modeling will lead to potentially novel diagnostic and
therapeutic targets for the treatment of HF.
Recent investigations following LVAD support have
focused on the expression of individual genes or their
protein products and have found a significant regulation of
several, including downregulation of natriuretic peptides
(16,17), collagen (18,19), dystrophin (20,21), interleukins
(22), matrix metalloproteinases (23), metallothionein (24),
and tumor necrosis factor- (25). These results demonstrate
that mechanical support of the failing myocardium can
indeed induce significant changes in gene and/or protein
expression. Such reports have given us initial insight into
some of the molecular mechanisms that may be involved in
LVAD-mediated myocardial recovery. However, the recent
development of oligonucleotide microarray technology can
simultaneously examine the expression of thousands of
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genes. This technology could provide important insight into
a substantially greater number of specific genes, as well as
overall gene expression profiles characteristic of the reverse
remodeling process.
Rather than target a limited number of genes of interest,
we wished to gain broader insight into the potential molec-
ular mechanisms associated with LVAD-associated reverse
remodeling, particularly with regard to statistically signifi-
cant changes in myocardial gene expression. Herein we
describe experiments designed to test overall gene expres-
sion from patients both before and after LVAD support
using oligonucleotide microarray technology coupled with
various statistical analyses to: 1) validate that our approach
using microarrays recapitulates previously reported changes
in gene expression; 2) report statistically relevant changes in
gene expression detectable by these methods; 3) determine
whether differential patterns of overall gene expression can
indeed distinguish between patients before and after LVAD
support; and 4) investigate the possibility of using differen-
tial gene expression to more accurately stratify patients both
before and after LVAD support, in concordance with other
clinical data.
METHODS
Tissue sampling and ribonucleic acid (RNA) extraction.
Tissue was obtained from the LV free wall (toward the
apex) of six male patients at the time of LVAD placement
(HeartMate, Thoratec Corp., Pleasanton, California) and at
the time of myocardial explantation. The duration of
LVAD support in all patients ranged from two to four
months. The LV tissue obtained from surgery was imme-
diately frozen in liquid nitrogen and stored at 80°C. All
surgical procedures and tissue harvesting were performed in
concordance with the National Institutes of Health and
Duke University Institutional Review Board guidelines.
Caution was exercised to utilize only viable, nonischemic
cardiac tissue from both pre- and post-LVAD samples for
RNA extraction. Total RNA was extracted using the
Qiagen RNeasy kit (Qiagen, Inc., Valencia, California),
including the proteinase K digestion recommended by the
manufacturer for RNA extraction from muscular tissue.
Total RNA quality was assessed by 1.2% agarose-
formaldehyde gel electrophoresis to visualize the 18S and
28S ribosomal ribonucleic acid (rRNA). Subsequently,
RNA quality was more rigorously determined using Agilent
RNA 6000 chips coupled with the Agilent 2100 Bioana-
lyzer (Agilent Technologies, Palo Alto, California), where
500 ng was used to determine the 18S:28S rRNA ratio. All
RNA used in the current study met the minimum require-
ment of at least a 1.8 ratio of 18S:28S rRNA. The RNA
aliquots were stored at 80°C before use.
Microarray analysis. Expression analysis was performed
using Affymetrix HuGeneFL GeneChips, which allow
detection of approximately 6,800 known genes or novel
clones with homology to known genes (Affymetrix, Santa
Clara, California). Target chromosomal RNA was prepared
according to the manufacturer’s protocol. Arrays were hy-
bridized with the targets at 45°C for 16 h, then washed and
stained using the GeneChip Fluidics Station. The deoxy-
ribonucleic acid (DNA) chips were scanned with the Gene
Chip scanner, and the scanning results were processed by
the GeneChip Expression Analysis Algorithm (version 3.2),
with a target intensity of 500 (Affymetrix). Affymetrix chip
processing was performed at the Duke University Genome
Core Facility. In a concerted effort to minimize inherent
variability, all chips were processed on the same day, using
the same manufacturing lot of reagents and same Affymetrix
scanner, and all had scaling factors within 10% of the group
mean value.
Statistical analysis. Raw average difference values provided
by the Affymetrix analysis from each chip were used for all
statistical analyses. Paired t tests and multidimensional
scaling (MDS) of total gene expression profiles were per-
formed using Partek software (Partek, Inc., St. Charles,
Missouri). In the simplest of terms, MDS is mapping of
high-dimensional data (6,800 genes per patient) into
low-dimensional space, such that the distances between
points mapped in low-dimensional Euclidean space repre-
sent the similarities, dissimilarities, or distances of the
original data. In this case, the distance between points in the
images approximates a dissimilarity between points in high-
dimensional space. Herein, metric MDS was performed
based on the Pearson dissimilarity (defined as [1  r]/2,
where r is the Pearson correlation) and mapped into
two-dimensional space (initialized with points drawn ran-
domly from a uniform distribution in the range of 1 to 1)
(26). Figures are generated by MDS to minimize a measure
of badness of fit, called stress, which depends on the
point-to-point dissimilarities in the data compared with the
distances in low-dimensional space. All images presented
herein had stress values from 0.002 to 0.031. In these
images, axes x and y represent the two Euclidean dimen-
sions into which the Pearson dissimilarities have been
mapped. Hierarchical clustering of patients according to
total or statistically filtered gene expression was performed
using Cluster and TreeView, made available from Michael
Eisen’s laboratory, using default settings, with hierarchical
clustering based on uncentered correlations with average
linkage clustering. Clustering of data according to biologic
function was performed using the coded electronic life
library suite of software from Incellico, Inc. (Durham,
Abbreviations and Acronyms
BNP  brain natriuretic peptide
DNA  deoxyribonucleic acid
HF  heart failure
LV  left ventricle/ventricular
LVAD  left ventricular assist device
MDS  multidimensional scaling
RNA  ribonucleic acid
rRNA  ribosomal ribonucleic acid
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North Carolina). For all tests, where applicable, p  0.05
was considered significant. It should be noted that for a
paired t test, there are caveats regarding multiple compari-
sons when analyzing 6,800 genes across only 12 samples.
The current data set does not withstand correction for
multiple comparisons; thus, we do not place a high degree of
confidence in the individual, gene-specific results from the
paired t test, particularly with regard to the smaller paired
groups of three patients, with the exception of those genes
we further validated using Northern blot analysis. Fold
change calculations were performed using methods previ-
ously published (27). Briefly, the mean value of each group
was taken, and a mean average difference value of 20 was
brought up to 20, based on previous data suggesting that
average difference values below 20 were unreliable or unde-
tectable. The mean average difference of each group was
then compared, and the relative fold change was calculated
based on the comparison.
RESULTS
LVAD-mediated regulation of gene expression. To elu-
cidate genomic changes that occur following ventricular
unloading in the LVAD-associated reverse remodeling
process, we analyzed differential gene expression in paired
LV free wall samples from six male patients with end-stage
cardiomyopathy obtained at the time of device placement
(pre-LVAD) and following 2 months of mechanical
support (post-LVAD) (six paired samples). Gene expres-
sion values were determined using HuGene FL oligonucle-
otide microarrays from Affymetrix, which provide detection
of 6,800 known human genes (or novel clones with
homology to know human genes). Paired statistical analysis
of the gene expression data revealed a significant reduction
in expression of genes previously reported to be downregu-
lated following LVAD support (at the level of messenger
RNA and/or protein expression), including collagen
(18,19), dystrophin (20,21), interleukin-8 (22), matrix met-
alloproteinase (23), metallothionein (24), and tumor necro-
sis factor- (p  0.05) (Table 1) (25). Furthermore, several
hallmark genes associated with HF, such as brain natriuretic
peptide (BNP), were also significantly downregulated fol-
lowing LVAD support, as previously described (p  0.05)
(Table 1) (16,17). In all, 530 genes were regulated in a
statistically significant manner in a comparison of pre- and
post-LVAD samples: 295 genes were upregulated and 235
were downregulated (supplemental Data of Table 1).
Among these were several genes of particular interest in the
setting of HF; however, numerous others have not been
previously associated with cardiac function, HF, or reverse
remodeling.
Statistically distinct pre- and post-LVAD gene expres-
sion profiles. Although investigation of statistically signif-
icant differential gene expression at the individual gene level
is important, we also wanted to determine whether the
overall genomic profile could segregate patients according to
pre- or post-LVAD status. Therefore, we wished to visu-
alize and analyze overall data structure in dimensional space
using multidimensional scaling (see Methods). This analysis
demonstrated a distinct separation between the pre- and
post-LVAD groups, indicating that there is indeed a
genomic signature of changes in gene expression associated
with LV reverse remodeling following LVAD support (Fig.
1). To further analyze the effect of LVAD support on gene
expression, Figure 1 also presents the Pearson correlation
matrix on which the MDS was based. The mean correlation
was 0.884 within the pre-LVAD group and 0.927 within
the post-LVAD group, but only 0.802 between the groups.
Of the 462 possible assignments of the 12 profiles to two
groups of six patients, the assignment with the lowest mean
correlation between groups was indeed that of the pre- and
post-LVAD groups (p  0.002), clearly demonstrating the
robust and significant effect of LVAD support on gene
expression. Interestingly, both methods suggest there was
greater gene expression diversity in the pre-LVAD group,
including a separation of the pre-LVAD group into two
groups of three patients, although there was a greater
similarity in the entire post-LVAD group gene expression
profile.
Gene expression profile segregates patients concordant
with HF etiology. Subsequent analysis of individual pa-
tient data (to which the investigators were previously
blinded) showed that members of both groups shared
several characteristics that could not adequately distinguish
them, including age, duration of diagnosed illness, duration
of LVAD support, and similar pharmacologic treatment
before LVAD support (Table 2). However, there was a clear
segregation of these two groups of patients based on their
apparent HF etiology, as determined both clinically and
pathologically after explantation (Table 2). The pre-LVAD
group of three patients with gene expression patterns most
distinct from the post-LVAD group had nonischemic,
idiopathic dilated cardiomyopathy (Table 2 [nonischemic
patients 1-3], Fig. 2A), whereas the pre-LVAD patients
most similar to the post-LVAD group had ischemic car-
diomyopathy (Table 2 [ischemic patients 4-6], Fig. 2A).
In light of the fact that MDS of the entire gene
expression data revealed patient distinction according to HF
etiology, we wished to determine whether data from the
genes found by the paired t test to be significantly regulated
Table 1. Validation of Microarray Method
GenBank
No. Gene p Value
Fold
Change
M31776 Brain natriuretic peptide 0.046 4.2
X60382 Collagen 0.047 3.0
L35854 Dystrophin 0.019 5.6
U11877 Interleukin-8 0.010 9.3
X64177 Metallothionein 0.024 2.4
D50477 Matrix metalloproteinase 0.036 4.0
U12595 Tumor necrosis factor- 0.032 1.6
Statistically significant regulation of genes detected by our methods for which similar
changes have previously been reported following left ventricular assist device support
(11–20). Statistical significance (p  0.05) determined by the paired t test.
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following LVAD support would demonstrate a similar
pattern of distinction. Importantly, gene expression data
from the 530 genes found to be significantly altered after
LVAD support (by paired t test), analyzed by MDS,
showed a similar pattern of separation between the pre- and
post-LVAD groups, as well as a more distinct segregation of
the pre-LVAD group when preclassified according to HF
etiology (Fig. 2B). Separation of the pre- and post-LVAD
groups, similar to that described earlier using MDS, was
found by the conventional Cluster and TreeView programs
(another method of statistically valid visualization and
analysis of data structure), accompanied by separation of
pre-LVAD patients according to their clinical history and
HF etiology (Fig. 3). Thus, the data clearly demonstrate
that individual LVAD status and HF etiology could be
distinguished using multiple statistical methods to analyze
transcriptional profiling. Due to the lack of a current “gold
standard” method for analyzing gene expression data sets,
we employed several statistical methods and believe it is an
important finding that all methods reached similar conclu-
sions.
HF etiology-specific changes in gene expression. Our
ability to classify patients according to HF etiology by gene
expression profile warranted further investigation of
Figure 1. Multidimensional scaling (MDS) and similarity matrix/exact test demonstrating clear and significant effect of left ventricular assist device
(LVAD) support on gene expression. (A) All gene expression data for pre-LVAD (green) and post-LVAD (red) patients (6,800 average difference values
from Affymetrix per patient) were subjected to MDS using Pearson dissimilarities. The image represents convergence of the MDS algorithm, stress
(measure of image validity) 0.03. (B) Similarity matrix based on the Pearson correlation of the 12 samples (6 pre- and 6 post-LVAD). Following an exact
test (random combinations of the 12 samples assigned to two groups), the most significantly divergent was the actual pre- and post-LVAD grouping, with
a significance value of 0.002, illustrating the significant effect of LVAD support on gene expression.
1099JACC Vol. 41, No. 7, 2003 Blaxall et al.
April 2, 2003:1096–106 Pre- and Post-LVAD Gene Expression
Table 2. Patient Data Before Left Ventricular Assist Device Support
Pt.
No. Clinical Description Pathologic Description Diagnosis* Age (yrs) Gender
LVAD
Duration (days) LVEF Patient History Medications†
1 Nonischemic IDC, CHF,
and TdeP (Mod. enl.)
IDC, very mild CAD, mild
fibrosis (nonischemic
distribution)
5 61 M 47 15% Hypercholesterolemia,
lipidemia, gout
Aspirin, Ativan, Coumadin,
Lanoxin, Lasix, Toprol,
Vasotec, Zocor, Zyrtec
2 Nonischemic IDC, CHF
(HB) (Sev. enl.)
IDC, no CAD, mild
fibrosis immediately
surrounding LVAD tube
5 52 M 66 10% VT, HB, pacemaker,
hyperthyroidism,
PPH, acute renal
failure
Albuterol, amiodorone, aspirin,
Carvedilol, digoxin, folate,
KCl, Lasix, lisinopril,
thiamine, Trazodone,
Zaroxolyn
3 Nonischemic IDC
(Mod. enl.)
IDC, no CAD, mild
fibrosis, (nonischemic
distribution)
3 64 M 64 15% Diabetes, edema,
cough/sputum
Coumadin, digoxin, insulin, KCl,
Lasix, Restoril, spironolactone,
Zaroxolyn
4 Ischemic CM, CHF,
post-CABG
(Mild. enl.)
Ischemic, CAD, bypass
grafts, mild biventricular
dilation
7 45 M 76 10% Diabetes, hypertension
hyperlipidemia,
renal insufficiency
Aspirin, captopril, digoxin,
insulin, Lasix, Zaroxolyn
5 Ischemic CM,
hypertensive ICM
(Mild. enl.)
Ischemic, CAD,
atherosclerosis, fibrosis,
mild biventricular
dilation
6 53 M 53 15% Hypertension, AF,
renal insufficiency
Atorvastatin, digoxin, furosemide,
KCl, losartan, spironolactone,
warfarin, Zaroxolyn
6 Ischemic CM, CAD, MI
4, CHF (Mild. enl.)
Ischemic, CAD, bypass
grafts, stents, multiple
infarcts
5 53 M 34 10% Diabetes, bronchitis,
COPD,
hypertension,
hyperlipidemia
Accupril, aspirin, Benadryl,
Colace, Combivent, digoxin,
Lasix, metformin, Zantac
Mean 5.2  0.2 Mean 54.6  1.0 Mean 56.6  2.3
*Years since initial diagnosis of heart failure. †Medications taken prior to LVAD placement. Clinical data from patients were obtained following initial gene expression data analysis based on segregation of patients before LVAD.
AF atrial fibrillation; CABG coronary artery bypass grafting; CAD coronary artery disease; CHF congestive heart failure; CM cardiomyopathy; COPD chronic obstructive pulmonary disorder; HB heart block; ICM
hypertensive ischemic cardiomyopathy; IDC  idiopathic dilated cardiomyopathy; LVEF  left ventricular ejection fraction; MI  myocardial infarction; Mod. enl. or Sev. enl.  moderately or severely dilated left ventricular chamber;
PPH  primary pulmonary hypertension; Pt.  patient; TdeP  torsades de pointes; VT  ventricular tachycardia.
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Figure 2. Multidimensional scaling (MDS) of pre- and post-left ventricular assist device (LVAD) gene expression. (A) Raw data classified according to
segregating patient clinical characteristics were subjected to MDS. Pre-1 (yellow) and post-1 (red) represent nonischemic patients, whereas pre-2 (blue)
and post-2 (green) represent ischemic patients. (B) Raw gene expression data from the 530 genes determined to be significant by paired t test analysis,
classified according to segregating patient clinical characteristics and subjected to MDS. The images represent convergence of the MDS algorithm, stress
for both (measure of image validity) 0.05. Note the limitation of program-assigned color schemes.
LVAD-mediated changes in gene expression of ischemic
and nonischemic patients. Indeed, paired t test analysis
demonstrated HF etiology-specific differences in gene ex-
pression following LVAD support: ischemic patients dem-
onstrated significant changes of 247 genes (122 upregulated
and 125 downregulated) (supplemental data of Table 2),
whereas nonischemic patients showed a significant regula-
tion of 784 genes (490 upregulated and 294 downregulated)
(supplemental data of Table 3). These data further support
our finding that the transcriptional profile of ischemic
Figure 3. Hierarchical clustering using Cluster and Treeview. Data for these programs require different names for each sample, hence 1-3 represent
nonischemic patients and 4-6 represent ischemic patients. (A) Hierarchical clustering of raw data; note the segregation of the nonischemic patients and
relative similarity of ischemic patients post-left ventricular assist device (LVAD). (B) Hierarchical clustering of raw data from the 530 genes found to be
significantly regulated by the paired t test. Note the distinct separation of pre- and post-LVAD, along with segregation of the nonischemic and ischemic
patients pre-LVAD.
Table 3. Genes Common to Ischemic and Nonischemic Patients Before and After Left Ventricular Assist Device Support
Gene
ID Description
Nonischemic
Patients
(Fold Change)
Ischemic
Patients
(Fold Change)
S75578 4-Aminobutyrate aminotransferase 18.5 1.3
U36221 Human pancreatic zymogen granule membrane protein GP-2 (a.k.a., EGF-1) 18.0 4.5
M37755 Human pregnancy-specific 1-glycoprotein gene PSGGA (a.k.a., actinin-1) 12.9 1.5
U07919 Human aldehyde dehydrogenase-6 12.4 2.5
X51956 Human ENO2 gene for neuron-specific (gamma) enolase 10.1 2.5
X14789 H. sapiens -A crystallin (a.k.a., HSP-20) 9.9 9.3
M64936 Homosapiens retinoic acid-inducible endogenous retroviral DNA 5.7 6.2
HG3740 Basic transcription factor 2, 34-Kda subunit 5.4 1.8
U83192 Human postsynaptic density protein 95 (PSD95) (a.k.a., guanylate kinase-1) 3.7 4.3
D38549 Human mRNA for KIAA0068 gene 3.2 1.6
M59465 Human tumor necrosis factor- (inducible protein A20) 3.0 1.6
M62302 Human growth/differentiation factor 1 (GDF-1) (a.k.a., TGF-1) 2.7 1.3
D80004 Human mRNA for KIAA0182 gene 2.2 2.7
U29175 Human transcriptional activator (BRG-1) 2.0 1.3
L10413 Human farnesyltransferase -subunit 1.8 1.2
U37146 Human silencing mediator of retinoid and thyroid hormone action (SMRT) (a.k.a., Myb3) 1.6 1.2
L06133 Human putative Cu-transporting P-type ATPase 1.5 1.5
D50857 Human DOCK180 protein (dedicator of cytokinesis) 1.3 1.4
D90084 Human pyruvate dehydrogenase -subunit 1.3 1.4
U78798 Human TNF receptor associated factor-6 (TRAF-6) 1.9 1.1
L35251 Homosapiens extracellular matrix protein (myofibrillar associated protein MFAP-3) 2.1 1.4
X71490 H. sapiens mRNA for vacuolar proton ATPase, subunit D 2.3 3.1
J04823 Human cytochrome c oxidase subunit VIII (COX8) 3.3 1.8
U72512 Human B-cell receptor associated protein (hBAP) 3.3 1.4
L35854 Human dystrophin (dp140) 3.3 1.8
M55420 Human IgE chain 4.2 3.2
Z83805 H. sapiens axonemal dynein heavy chain 9.2 3.4
M92269 Human L-type calcium channel 11.0 1.2
HG3991 Cpg-enriched Dna, clone E18 89.1 17.5
Paired t test analyses of patients from ischemic and nonischemic groups were compared and merged, identifying only those genes common to both lists with p  0.05. Genes
in italics represent those reciprocally regulated in ischemic versus nonischemic patients following left ventricular assist device support. Gene names are presented as listed by the
Affymetrix software. Parenthetical alias gene names were obtained from the Prosite data base in comparison with GenBank, using the CELL suite from Incellico.
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patients before LVAD support was more closely related to
the post-LVAD transcriptional profile than that of patients
with nonischemic, idiopathic dilated cardiomyopathy. In-
terestingly, a comparison of statistically significant changes
in gene expression following LVAD support from the
ischemic and nonischemic patients found only 29 genes that
were common to both groups. However, of these 29 genes,
the expression of 13 was reciprocally regulated in ischemic
versus nonischemic samples. Hence, the regulation of only
16 genes was truly shared between groups (Table 3).
Furthermore, nonischemic patients demonstrated a signifi-
cant downregulation of several genes, as previously de-
scribed following LVAD support, including BNP (16,17),
collagen (18,19), interleukin-8 (22), and matrix metallopro-
teinase (28). Conversely, ischemic patients showed upregu-
lation of interleukin-8 and no significant regulation of the
other genes (see paired t test data in supplemental data of
Tables 2 and 3). Interestingly, several hallmark genes of HF,
such as -myosin heavy chain and skeletal -actin were also
significantly downregulated following LVAD support in
nonischemic patients, although there was no change or
upregulation of these genes in ischemic patients (Fig. 4A).
These data were corroborated with Northern blot analysis of
these two genes, which were qualitatively similar to the
microarray data in terms of expression and significance (Fig.
4B). These data underscore the divergent phenotypic and
genomic LVAD-mediated reverse remodeling that occurs
in ischemic and nonischemic cardiomyopathies.
Regulation of metabolic genes. Finally, genes determined
to be significantly regulated following LVAD support in
patients, by the paired t test, were clustered according to the
biologic process by linking the GenBank identification
number with the Gene Ontology data base using the coded
electronic life library cross-referencing tool. This clustering
demonstrated an enhancement (albeit nonsignificant) in the
percentage of metabolic genes changed significantly follow-
ing LVAD support, as compared with the entire population
of genes represented on the microarray (Fig. 5), similar to
the previously described regulation of metabolic genes in
HF (29,30). A small sample of this type of clustering is
presented in Figure 5A, along with a table representing the
number and percentage of genes in families of biologic
function both from the t test analysis and as represented on
the entire array (Fig. 5B).
DISCUSSION
Herein we have reported our investigation of global changes
in gene expression following LVAD support, using a
statistically oriented approach in paired human samples,
thus providing a host of potentially novel diagnostic and/or
therapeutic targets for future investigation. Our current
study provides an expanded view of the significant changes
in gene expression associated with LVAD support of the
failing human heart. Furthermore, the data demonstrate a
more homogeneous gene expression profile following
LVAD support, as compared with pre-LVAD samples,
suggesting that there may be a genomic signature of
LVAD-associated reverse remodeling.
Differential pre- and post-LVAD gene expression. In a
statistically significant manner, we found that of 7,000
genes, 295 were upregulated and 235 were downregulated
following LVAD support. Although the expression of some
genes already known to be altered by LVADs were found to
be similarly changed in this study, the majority of the
differential gene expression found consisted of genes not
previously known to be affected by LVAD support, includ-
ing several genes without a clear connection to cardiomy-
opathy. Interestingly, when clustering differential post-
LVAD gene expression according to functional processes, a
Figure 4. Heart failure etiology-specific regulation of gene expression. (A)
Raw Affymetrix average difference hybridization intensity values for
-myosin heavy chain (MHC) and skeletal (SK) -actin, demonstrating
the divergent regulation of gene expression following LVAD support in
different heart failure etiologies. (B) Signal to glyceraldehyde-6-phosphate
dehydrogenase ratio of Northern blot data for -MHC and SK -actin,
demonstrating concordance of trends in data seen by the Affymetrix
GeneChip. Isch ischemic patients; NI nonischemic patients. Changes
in gene expression values for these genes found by both microarray (A) and
Northern Blot (B) p  0.05 in NI patients and not significant in Isch
patients, determined by paired t test.
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high percentage of genes involved in metabolism were found
to have significantly altered expression. These included
genes involved in deoxyribonucleic acid, RNA, and protein
metabolism, as well as general energy pathways. Thus, it
appears that while the heart is mechanically unloaded, the
process of reverse remodeling is associated with significant,
active changes in cellular metabolic pathways.
Our results demonstrate that pre- and post-LVAD sam-
ples have distinct and statistically significant segregating
genomic footprints, providing evidence that the reverse
remodeling process and associated phenotypic changes after
LVAD support are accompanied by distinct changes in gene
expression. It is probable that among the 530 genes that
were regulated in a statistically significant manner following
LVAD support are genes indicative and predictive of the
reverse remodeling process. Of particular interest are genes
that previously have not been considered in the setting of
HF. Further investigation of these genes will be required to
understand their specific roles in both cardiomyopathy and
the reverse remodeling process. Importantly, these genes
may provide a host of novel targets for future diagnostic or
therapeutic indications.
Figure 5. Clustering of genes by functional process. Genes found to be significant by the paired t test were clustered according to the biologic process by
linking the GenBank accession number with the Gene Ontology database. (A) Small screenshot of the entire cluster by Gene Ontology biologic process.
(B) Number and percentage of significant genes in relation to representation on entire chip. Note that not all genes represented on the chip are annotated
in the Gene Ontology data base, hence only 397 of the 530 genes are represented here.
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Genomic patient stratification concordant with HF eti-
ology. Previously, several investigators have suggested that
patients with nonischemic cardiomyopathy undergo more
extensive reverse remodeling than ischemic patients follow-
ing LVAD support (6,31). Our data certainly support that
notion, demonstrating much more extensive changes in
gene expression following LVAD support in nonischemic
versus ischemic patients. Indeed, it seems intuitive that the
remaining viable myocardium in ischemic patients is most
probably much more functional than the more globally
dysfunctional tissue found in idiopathic dilated myocar-
dium. Therefore, a heart that has undergone extensive
remodeling over time (i.e., idiopathic dilated cardiomyopa-
thy) would undergo dramatic changes following mechanical
support. In contrast, the myocardium within an ischemic
heart generally composed of both scar tissue and viable,
functional myocardium may undergo less dramatic changes
under mechanical support. Importantly, our segregation of
the patients’ genomic response to LVAD support was
obtained in blinded fashion, underscoring the clearly diver-
gent, HF etiology-specific changes in gene expression.
Interestingly, our serendipitous inclusion of three ischemic
and three nonischemic patients may provide the explanation
for why we were unable to find all the genes previously
associated with LVAD support, as the majority of these
studies have been carried out strictly in nonischemic pa-
tients. When considering vast human heterogeneity, it is
striking that a small sample size could clearly distinguish the
difference in HF etiology by myocardial gene expression.
Subsequently, we determined differential LVAD-mediated
regulation of gene expression in these two divergent types of
HF. Importantly, we found significant differences in gene
expression resulting from LVAD support when starting
with either a failing ischemic or nonischemic heart.
Surprisingly, among the expression of hundreds of genes
that were significantly regulated, only 16 were similarly
regulated in a significant fashion. Also of interest was the
fact that in the paired t test analysis, data from previous pre-
versus post-LVAD studies of four individual genes was
corroborated in the nonischemic patients, whereas there was
no corroboration in the ischemic patients, underscoring the
divergent, HF etiology-specific response to LV unloading.
Interestingly, several hallmark genes of HF, such as skeletal
-actin and -myosin heavy chain, were downregulated
following LVAD support in the nonischemic patients,
whereas there was no change or a trend toward upregulation
of these genes in the ischemic patients. This disparity may
explain, in part, why less hallmark genes of HF previously
described were found to be significantly downregulated
following LVAD support in the complete cohort of six
patients. Our findings underscore the well-described phe-
notypic distinction between these two types of cardiomyop-
athy and suggest different mechanisms of LVAD-mediated
recovery dependent on HF etiology.
Potentially predictive value of the study. Several groups
have also envisioned the use of LVADs as a potential
“bridge to recovery,” where the extent of recovery in certain
patients would be sufficient to allow weaning from LVAD
support and obviate the necessity of transplantation (32–
35). However, there has been substantial variability in the
reported patient response to LVAD weaning. Importantly,
the investigators of the Randomized Evaluation of Mechan-
ical Assistance for the Treatment of Congestive Heart
failure (REMATCH) trial recently published exciting re-
sults demonstrating that long-term LVAD support provides
significantly improved morbidity and mortality, as com-
pared with optimized medical management, in patients with
end-stage heart failure who are ineligible for transplantation
(36). One of the central challenges of long-term LVAD
support, or particularly the bridge to recovery, is choosing
the “correct” patient(s) for these procedures, partly due to
a relative paucity of data on the mechanisms of reverse
remodeling. A limited number of methods have been
proposed to “predict” the patient’s response to long-term
LVAD or weaning, such as pre-LVAD creatinine levels
(10), decreased circulating levels of BNP (17), duration of
illness (2), nonischemic cardiomyopathy (6,31,32), de-
creased bilirubin levels (37), age (37), and pre-implant
ventilation (37). However, these reports also urge caution in
predicting an outcome based on a single factor. Along with
the development of predictive methodologies, serial deter-
mination of cardiac function (and recovery) during LVAD
support, determination of optimal support modalities, med-
ical therapies, and weaning strategies will need to be
developed. Although the salutary effect of LVAD support is
evident, the molecular mechanisms underlying reverse re-
modeling have not been well described.
Our study demonstrates that the phenotypic changes that
occur following LVAD support are associated with geno-
typic changes in the form of significantly altered myocardial
gene expression profiles. We believe combining our meth-
ods for statistically analyzing genomic profiles reported
herein with a variety of data, including but not limited to
clinical history and HF etiology, may provide promising
diagnostic tools to determine, a priori, which patients would
most likely respond favorably to long-term LVAD or weaning
from the device in lieu of heart transplantation. Indeed, studies
are now attempting to use multimodal data (including
microarray and clinical data) to predict the cellular or patient
response to pharmacological and/or surgical intervention in
several disease states, particularly cancer (38,39).
Herein we have described our ability to statistically
distinguish patients’ LVAD status and HF etiology using
oligonucleotide microarrays. Furthermore, we have identi-
fied differential expression of numerous genes significantly
associated with mechanical unloading of the failing heart,
both in general and specific to ischemic or nonischemic HF
etiology. These data and statistical methods of microarray
analysis provide substantial insight into the potential mech-
anisms of reverse remodeling and, with further study and
development, may facilitate the prognostic prediction of the
individual patient response to LVAD support.
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